Zydus drug Virafin gets DCGI nod, firm says it reduces need for oxygen support, recovery time
3 years, 8 months ago

Zydus drug Virafin gets DCGI nod, firm says it reduces need for oxygen support, recovery time

India Today  

Zydus Cadila has received emergency use approval from the Indian regulator for the use of its anti-viral drug 'Virafin'. Pharma giant Zydus says 91.15 per cent of adult patients treated with Virafin tested negative using RT-PCR in seven days. Virafin helps body cope with Interferon Alpha deficiency In its Phase III clinical trials, researchers found that a higher proportion of patients administered Virafin tested negative for the infection by the seventh day. What does clinical trial data for Virafin says It was found during the Phase III clinical trials of Virafin that patients administered the anti-viral drug showed considerable improvement on the eighth day as compared to the existing treatment for Covid-19 in moderate cases. In the Phase II clinical trials, Zydus found that there was a significant reduction of the viral load among Covid-19 patients treated with Virafin.

India Trials Patients Viral Drug Phase Clinical Zydus Interferon Zydus Cadila Virafin Nod Firm Interferon Alpha  recovery  nod  firm  phase  virafin  oxygen  drug  clinical  viral  reduces  trials  gets  zydus  support  interferon  need  covid19  patients

History of this topic

Zydus Cadila to Submit Additional Data on Covid Vaccine to DGCI This Week: Sources
3 years, 5 months ago

Zydus Cadila to Submit Additional Data on Covid Vaccine to DGCI This Week: Sources

News 18  

The Gujarat-based pharma company Zydus Cadila is expected to provide additional data related to immunogenicity and safety of its vaccinate candidate ZyCoV-D to the Drugs Controller General of India this week, according to sources. Zydus’ three-dose vaccine was reported to be 66.6 per cent effective against symptomatic Covid cases and 100 per cent effective for moderate infection. NITI Aayog member …

Zydus Cadila seeks human trial approval for Covid-19 antibody cocktail
3 years, 6 months ago

Zydus Cadila seeks human trial approval for Covid-19 antibody cocktail

India Today  

Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild Covid-19, as the country grapples with a shortage of medicines and vaccines needed to effectively tackle a devastating second wave of the pandemic. READ: Covid Antibody Cocktail will reduce hospitalisation, can be given to children: Dr Naresh Trehan The therapy is a cocktail of …

Zydus Cadila Prices Covid-19 Medicine 'Virafin' at Rs 11,995 Per Dose
3 years, 7 months ago

Zydus Cadila Prices Covid-19 Medicine 'Virafin' at Rs 11,995 Per Dose

News 18  

Days after receiving approval for emergency use of its medicine ‘Virafin’ to treat moderate cases of COVID-19, Zydus Cadila has reportedly pegged the price of the drug at Rs 11,995 per dose. Zydus Cadila has claimed outlined this medicine, technically referred to as Pegylated Interferon alpha-2b, can be given when there is a moderate degree of infection. During the phase …

Zydus announces prices for its Covid drug Virafin approved by DCGI for use in moderate cases
3 years, 7 months ago

Zydus announces prices for its Covid drug Virafin approved by DCGI for use in moderate cases

India Today  

Drug Firm Zydus Cadila has set the price of its medicine ‘Virafin' at Rs 11,995 per dose. After the DCGI's approval for use of this medicine in the treatment of moderate cases of Covid-19, the pharma giant has begun dispatching doses to its vendors. 'Virafin,' a single-use medication obtained emergency use clearance from the Drug Controller General of India, the …

Used to treat Hepatitis C, here's how Zydus' repurposed drug Virafin can aid recovery of Covid patients
3 years, 8 months ago

Used to treat Hepatitis C, here's how Zydus' repurposed drug Virafin can aid recovery of Covid patients

India Today  

Zydus Cadila's Pegylated Interferon alpha-2b drug, 'Virafin', has received Emergency Use Approval from DCGI, the Drugs Controller General of India. Pharma giant Zydus Cadila says its anti-viral drug Virafin can not only reduce the need for medical oxygen but also improve recovery time among Covid-19 patients. Earlier launched as PegiHep, the drug was being used to treat Hepatitis C. A …

Zydus Cadila Seeks DCGI Nod for Use of Hepatitis Drug for Covid-19 Treatment
3 years, 8 months ago

Zydus Cadila Seeks DCGI Nod for Use of Hepatitis Drug for Covid-19 Treatment

News 18  

Drug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator Drugs Controller General of India for additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19. Phase-III clinical trials with Pegylated Interferon Alpha 2b, which company sells under the brand name 'PegiHep' has shown promising results in treating COVID-19, Zydus Cadila said …

Zydus Cadila seeks DCGI nod for use of hepatitis drug in Covid-19 treatment
3 years, 8 months ago

Zydus Cadila seeks DCGI nod for use of hepatitis drug in Covid-19 treatment

India Today  

Zydus Cadila on Monday said it had sought approval from the Drugs Controller General of India for use of its viral hepatitis drug in treating Covid-19 after its Phase 3 clinical trials showed promising results. The drug reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate Covid-19 patients, Zydus Cadila said in a statement. “With …

Zydus Cadila's COVID Vaccine Offers Immunity in Phase 1/2 Trials
3 years, 11 months ago

Zydus Cadila's COVID Vaccine Offers Immunity in Phase 1/2 Trials

The Quint  

The trial has been reviewed by an independent Data Safety Monitoring Board and reports have been submitted to Central Drugs Standard Control Organisation regularly for the update on safety outcome. Pankaj R. Patel, Chairman of the Zydus Group said, "After establishing safety in phase I clinical trial, ZyCoV-D has now completed Phase II clinical trials and the vaccine has been …

Zydus Cadila Gets DGCI Nod for Phase 3 Covid Vaccine Clinical Trials with Biological Therapy
4 years ago

Zydus Cadila Gets DGCI Nod for Phase 3 Covid Vaccine Clinical Trials with Biological Therapy

News 18  

Drug firm Zydus Cadila on Friday said it has received the approval fromthe Drugs Controller General of India to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients. In a regulatory filing, Zydus Cadila said it has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy …

Zydus Cadila gets DCGI nod for Phase 3 trial of repurposed drug to treat Covid-19
4 years ago

Zydus Cadila gets DCGI nod for Phase 3 trial of repurposed drug to treat Covid-19

India Today  

Gujarat-based drug manufacturer Zydus Cadila today said it has received approval from the Drugs Controller General of India to conduct Phase 3 clinical trials on its re-purposed drug that it hopes to use for Covid-19 treatment. The drug, Pegylated Interferon alpha-2b, 'PegiHepTM', is an approved drug that been in use since 2001 and is now being re-purposed to treat Covid-19 …

Zydus Cadila Completes Phase-2 Clinical Trial in Covid-19 Patients with Biological Therapy
4 years, 1 month ago

Zydus Cadila Completes Phase-2 Clinical Trial in Covid-19 Patients with Biological Therapy

News 18  

New Delhi: Drug firm Zydus Cadila on Thursday said it has successfully completed a phase 2 clinical trial In COVID-19 patients with its biological therapy, 'PegiHep', and it will now begin phase 3 clinical trial. In a regulatory filing, Zydus Cadila said "it has successfully completed a phase 2 clinical trial in COVID-19 patients with its biological therapy, Pegylated Interferon …

Zydus Cadila to commence phase II clinical trials of COVID-19 vaccine from Aug 6
4 years, 4 months ago

Zydus Cadila to commence phase II clinical trials of COVID-19 vaccine from Aug 6

The Hindu  

Drug firm Zydus Cadila on Wednesday said the phase I clinical trial of its COVID-19 vaccine candidate, ZyCoV-D, has been completed and it will commence phase II clinical trials from August 6. “The company reports that the doses of the vaccine administered to healthy volunteers in the phase I clinical trial, which began on July 15, 2020, has been well …

Potential COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials
4 years, 5 months ago

Potential COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials

The Hindu  

A potential COVID-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd. has got the nod from the Drugs Controller General of India for human clinical trials, according to a government source. Somani has given approval for the phase I and II clinical trials of the potential novel coronavirus vaccine developed by Zydus Cadila Healthcare Ltd. on Thursday after …

Discover Related